Entera Bio's EB613 data selected for presentation at ENDO 2026 May 28, 2026 08:50AM
Entera’s EB613, First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis - Single Tablet Data Selected for Late Breaking Oral Presentation at ENDO 2026 Annual Meeting; Additional Oral Peptide Pipelin May 28, 2026 08:50AM
Entera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide Programs May 8, 2026 04:05PM
Entera Bio to Host Key Opinion Leader Webinar Highlighting the Osteoporosis Treatment Landscape and the Opportunity for EB613 Apr 14, 2026 08:45AM
Entera Bio raises $10 million from BVF Partners in private placement Apr 2, 2026 08:46AM
View Older Stories

Apr 2, 2026 08:45AM Entera Bio Announces Pricing of $10.0 Million Direct Investment by BVF Partners with Potential for up to $24.5 Million in Total Proceeds
Mar 27, 2026 04:05PM Entera Bio Announces Full Year 2025 Financial Results and Provides Business Updates
Mar 4, 2026 08:30AM Entera Bio submits streamlined Phase 3 protocol for oral osteoporosis drug
Mar 4, 2026 08:30AM Entera Bio Submits Streamlined Phase 3 Protocol to Initiate Registrational Program for EB613 in Postmenopausal Women with Osteoporosis
Feb 26, 2026 08:00AM Entera Bio to Participate in the Leerink Partners 2026 Global Healthcare Conference
Feb 26, 2026 08:00AM Entera Bio to Participate in the Leerink Partners 2026 Global Healthcare Conference
Feb 11, 2026 09:03AM Entera Bio board members purchase shares in open market transactions
Feb 11, 2026 09:00AM Entera Bio Announces Open Market Purchases of Company Stock by Board Members
Feb 9, 2026 08:50AM Entera Bio names former Pfizer executive as new chairman
Feb 9, 2026 08:50AM Entera Bio Appoints Former Pfizer Executive Geno J. Germano as Chairman of the Board Ahead of Key Milestones
Feb 4, 2026 08:02AM OPKO Health and Entera Bio expand partnership for oral PTH tablet
Feb 4, 2026 08:00AM OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism
Jan 21, 2026 08:31AM Entera Bio outlines Q1 2026 milestones for osteoporosis drug
Jan 21, 2026 08:30AM Entera Bio Announces Upcoming Q1 2026 Corporate Priorities and Pipeline Outlook
Jan 21, 2026 08:30AM Entera Bio Announces Upcoming Q1 2026 Corporate Priorities and Pipeline Outlook
Dec 23, 2025 08:30AM Entera Bio Congratulates the FNIH-ASBMR-SABRE Team on FDA’s Qualification of Total Hip BMD as Regulatory Endpoint: Huge Win for Osteoporosis Innovation
Dec 22, 2025 08:32AM Entera Bio reports preclinical data for once-daily hypoparathyroidism tablet
Dec 22, 2025 08:30AM Entera Bio Announces New Data Supporting Further Development of a Proprietary First-in-Class Oral, Long-Acting PTH Tablet for Patients with Hypoparathyroidism (EB612 Program)
Nov 18, 2025 08:00AM Entera Bio to Participate in the 8th Annual Evercore ISI Healthcare Conference
Nov 14, 2025 04:05PM Entera Bio Announces Third Quarter 2025 Financial Results and Business Updates
Oct 23, 2025 08:50AM Entera Bio reports bone density gains in early menopause trial
Oct 23, 2025 08:50AM Entera Bio Presents Positive New Clinical Data from EB613 Phase 2 Trial Demonstrating Significant Bone Density Improvements in Early Postmenopausal Women
Oct 16, 2025 08:45AM Entera Bio to present EB613 osteoporosis data at menopause conference
Oct 16, 2025 08:45AM Entera Bio to Present New Clinical Data from Phase 2 Trial of EB613 at the 2025 North American Menopause Society (NAMS) Annual Meeting
Sep 15, 2025 09:01AM Entera Bio presents oral GLP-2 tablet data at medical conference
Sep 15, 2025 09:00AM Entera Bio Reports Positive PK Data for First-in-Class Oral GLP-2 Tablet Treatment for Patients with Short Bowel Syndrome at the 2025 ESPEN Congress
Sep 8, 2025 08:32AM Entera Bio presents bone density improvements from EB613 osteoporosis drug
Sep 8, 2025 08:30AM Entera Bio Presents Positive Effects of EB613 on Both Trabecular and Cortical Bone in Postmenopausal Women with Osteoporosis at ASBMR 2025
Aug 28, 2025 08:05AM Entera Bio to present clinical data at September medical conferences
Aug 28, 2025 08:00AM Entera Bio to Unveil Clinical and Non-Clinical Data Across 3 Oral Peptide Programs at Upcoming September Conferences
Aug 8, 2025 04:05PM Entera Bio Announces Second Quarter 2025 Financial Results and Business Updates
Jul 28, 2025 07:30AM FDA allows Entera Bio to use bone density as primary endpoint for EB613 study
Jul 28, 2025 07:30AM Entera Bio Receives FDA Agreement on BMD as Primary Endpoint for EB613 Registrational, Phase 3 Study in Post-Menopausal Women with Osteoporosis
Jul 8, 2025 08:03AM OPKO Health and Entera Bio abstract selected for ESPEN Congress
Jul 8, 2025 08:00AM OPKO Health and Entera Bio Announce Abstract on PK/PD of Oral GLP-2 Tablet for the Treatment of Short Bowel Syndrome Selected for 2025 ESPEN Congress
Jun 26, 2025 08:00AM Entera Bio Data for EB613 Effects on Trabecular and Cortical Bone in Post-Menopausal Women with Osteoporosis Selected for Oral Presentation at ASBMR 2025 Annual Meeting
Jun 25, 2025 08:05AM OPKO Health (OPK) and Entera Bio (ENTX) Abstract for First-in-Class Dual GLP-1/Glucagon Tablet Candidate for Patients with Obesity and Metabolic Disorders Selected for Presentation
Jun 25, 2025 08:00AM OPKO Health and Entera Bio Abstract for First-in-Class Dual GLP-1/Glucagon Tablet Candidate for Patients with Obesity and Metabolic Disorders Selected for Presentation at the ENDO 2025 Annual Meeting
May 9, 2025 04:05PM Entera Bio Announces First Quarter 2025 Financial Results and Business Updates
Apr 15, 2025 08:32AM Entera Bio Ltd. (ENTX) Demonstrates Early Impact on Both Trabecular and Cortical Bone Compartments with 6 Months of Treatment in Post-Menopausal Women with Osteoporosis
Apr 15, 2025 08:30AM Entera Bio’s EB613 Demonstrates Early Impact on Both Trabecular and Cortical Bone Compartments with 6 Months of Treatment in Post-Menopausal Women with Osteoporosis - Highlighted as Oral Presentatio
Mar 28, 2025 04:05PM Entera Bio Announces Full Year 2024 Financial Results and Provides Business Updates
Mar 17, 2025 08:01AM OPKO Health (OPK) and Entera Bio (ENTX) Enter into Collaboration Agreement
Mar 17, 2025 08:00AM OPKO Health and Entera Bio Enter into Collaboration Agreement to Advance Oral GLP-1/Glucagon Tablet Candidate into the Clinic to Treat Obesity and Metabolic Disorders
Feb 24, 2025 08:30AM Entera Bio to Participate in Upcoming Events
Feb 19, 2025 08:00AM EFFECTS OF EB613 TABLETS [ORAL PTH(1-34)] ON TRABECULAR AND CORTICAL BONE USING 3D-DXA: POST-HOC RESULTS FROM PHASE 2 STUDY Accepted for Oral Presentation at World Congress on Osteoporosis, Osteoarthr
Jan 27, 2025 08:00AM Entera Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Nov 8, 2024 04:05PM Entera Bio Reports Q3 2024 Financial Results and Provides Business Updates
Sep 25, 2024 08:31AM Entera Bio Ltd. (ENTX) and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin Peptide Tablet Candidate
Sep 25, 2024 08:30AM Entera Bio and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide Tablet Candidate for Obesity and Metabolic Disorders
View Older Stories